CN1077107C - 杂环化合物、其制备和用途 - Google Patents

杂环化合物、其制备和用途 Download PDF

Info

Publication number
CN1077107C
CN1077107C CN97195822A CN97195822A CN1077107C CN 1077107 C CN1077107 C CN 1077107C CN 97195822 A CN97195822 A CN 97195822A CN 97195822 A CN97195822 A CN 97195822A CN 1077107 C CN1077107 C CN 1077107C
Authority
CN
China
Prior art keywords
group
alkyl
replaces
ethyl acetate
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97195822A
Other languages
English (en)
Chinese (zh)
Other versions
CN1223653A (zh
Inventor
百濑佑
松谷悦哉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN1223653A publication Critical patent/CN1223653A/zh
Application granted granted Critical
Publication of CN1077107C publication Critical patent/CN1077107C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN97195822A 1996-07-19 1997-07-17 杂环化合物、其制备和用途 Expired - Fee Related CN1077107C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP19110096 1996-07-19
JP191100/1996 1996-07-19
JP191100/96 1996-07-19
JP155177/1997 1997-06-12
JP15517797 1997-06-12
JP155177/97 1997-06-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN01119519A Division CN1349990A (zh) 1996-07-19 2001-05-18 杂环化合物、其制备和用途

Publications (2)

Publication Number Publication Date
CN1223653A CN1223653A (zh) 1999-07-21
CN1077107C true CN1077107C (zh) 2002-01-02

Family

ID=26483246

Family Applications (2)

Application Number Title Priority Date Filing Date
CN97195822A Expired - Fee Related CN1077107C (zh) 1996-07-19 1997-07-17 杂环化合物、其制备和用途
CN01119519A Pending CN1349990A (zh) 1996-07-19 2001-05-18 杂环化合物、其制备和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN01119519A Pending CN1349990A (zh) 1996-07-19 2001-05-18 杂环化合物、其制备和用途

Country Status (10)

Country Link
US (1) US6211215B1 (de)
EP (2) EP0912562A1 (de)
KR (1) KR20000065227A (de)
CN (2) CN1077107C (de)
AT (1) ATE338754T1 (de)
AU (1) AU3461697A (de)
CA (1) CA2260999C (de)
DE (1) DE69736642T2 (de)
ID (1) ID17851A (de)
WO (1) WO1998003505A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU742739B2 (en) * 1997-05-28 2002-01-10 Aventis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56 lck tyrosine kinases
US6180632B1 (en) 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
FR2766822B1 (fr) * 1997-07-30 2001-02-23 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA002525B1 (ru) † 1997-08-15 2002-06-27 Сефалон Инк. Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы
HUP0103761A3 (en) * 1998-10-08 2002-11-28 Takeda Chemical Industries Ltd Compositions for retarding change of hormone-dependent cancer into hormone-independent cancer and their use
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
WO2001035955A1 (en) * 1999-11-16 2001-05-25 Toray Industries, Inc. Benzene derivatives and use thereof as drugs
PE20011178A1 (es) * 2000-04-07 2001-11-19 Takeda Chemical Industries Ltd Compuestos heterociclicos y su produccion
CN1705649A (zh) 2000-06-29 2005-12-07 艾伯特公司 芳基苯基杂环基硫醚衍生物及其作为抑制细胞粘附的抗炎和免疫抑制剂的用途
KR20030013360A (ko) 2000-07-19 2003-02-14 다케다 야쿠힌 고교 가부시키가이샤 1-치환-1,2,3-트리아졸 유도체의 제조 방법
KR20040025881A (ko) * 2000-12-11 2004-03-26 다케다 야쿠힌 고교 가부시키가이샤 개선된 흡수성을 갖는 의약 조성물
EP1712550A3 (de) * 2000-12-22 2009-07-15 Ortho-McNeil Pharmaceutical, Inc. Substituite Triazoldiamin Derivate und ihre Verwendung als Kinase-Inhibitoren
DE60139025D1 (de) 2000-12-28 2009-07-30 Takeda Pharmaceutical Alkansäurederivate, verfahren zu deren herstellung und deren verwendung
SE0100567D0 (sv) * 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
WO2002087619A1 (en) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Preventive/therapeutic method for cancer
US20040116330A1 (en) * 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
KR100965201B1 (ko) 2001-06-12 2010-06-24 웰스테트 테라퓨틱스 코포레이션 대사 질환의 치료용 화합물
EP1439178A4 (de) * 2001-10-05 2005-11-16 Takeda Pharmaceutical Heterocyclische verbindungen, oxazolderivate, verfahren zu deren herstellung und deren verwendung
EP1444988A4 (de) 2001-11-13 2007-04-25 Takeda Pharmaceutical Krebsmittel
AU2002349477A1 (en) * 2001-11-26 2003-06-10 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
WO2003059907A1 (en) * 2002-01-17 2003-07-24 Takeda Chemical Industries, Ltd. Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
DE10258168B4 (de) * 2002-12-12 2005-07-07 Infineon Technologies Ag Integrierter DRAM-Halbleiterspeicher und Verfahren zum Betrieb desselben
ES2530235T3 (es) 2003-02-13 2015-02-27 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos
TW200505913A (en) * 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
TW200423931A (en) 2003-04-30 2004-11-16 Hoffmann La Roche Novel aniline derivatives, their manufacture and use as pharmaceutical agents
US7247649B2 (en) 2003-08-13 2007-07-24 Hoffmann-La Roche Inc. Oxazoles, their manufacture and use as pharmaceutical agents
CN100398536C (zh) * 2003-08-20 2008-07-02 爱密斯菲尔科技公司 用于口服传递glp-1化合物或mc4激动剂肽的化合物、方法和制剂
JP4767850B2 (ja) 2003-08-20 2011-09-07 エミスフィアー テクノロジーズ インコーポレイテッド グルカゴン様ペプチド（ｇｌｐ）−１化合物またはメラノコルチン４受容体（ｍｃ４）アゴニストペプチドの経口デリバリーのための化合物、方法および製剤
US7259262B2 (en) 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents
TW200612914A (en) 2004-03-05 2006-05-01 Hoffmann La Roche Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
TW200531688A (en) 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
TW200533346A (en) 2004-03-18 2005-10-16 Hoffmann La Roche Novel ether derivatives, their manufacture and use as pharmaceutical agents
US20080132699A1 (en) 2004-04-02 2008-06-05 Markus Ege Process For the Preparation of Diazine Derivatives
US7005526B2 (en) 2004-05-25 2006-02-28 Hoffmann-La Roche Inc. Thioether derivatives
US7163953B2 (en) 2004-05-25 2007-01-16 Hoffmann-La Roche Inc. Benzylether derivatives
US7288557B2 (en) 2004-09-21 2007-10-30 Hoffmann-La Roche Inc. Triazole derivatives
US7342030B2 (en) 2004-09-22 2008-03-11 Hoffmann-La Roche Inc. Indole derivatives
AR050652A1 (es) * 2004-09-24 2006-11-08 Hoffmann La Roche Derivados de oxazol, preparacion y uso como inhibidores de la tirosina quinasa
US20060116407A1 (en) * 2004-11-22 2006-06-01 Birgit Bossenmaier Amide derivatives
KR20080041662A (ko) 2005-07-22 2008-05-13 다케다 야쿠힌 고교 가부시키가이샤 조기 배란 예방제
TW200738680A (en) 2005-08-04 2007-10-16 Hoffmann La Roche Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents
CA2616075A1 (en) * 2005-08-08 2007-02-15 Hans-Willi Krell Pyrazole derivatives, their manufacture and their use as pharmaceutical agents
EP1968596A4 (de) * 2005-12-22 2010-12-01 Icagen Inc Calciumkanalantagonisten
WO2008034579A1 (en) * 2006-09-20 2008-03-27 F. Hoffmann-La Roche Ag 2-heterocyclyl-5-phenoxymethylpyridine derivatives as anticancer agents
CA2727528A1 (en) * 2007-06-14 2008-12-18 Osta Biotechnologies Heme-oxygenase inhibitors and use of the same in the treatment of cancer and diseases of the central nervous system
WO2010026993A1 (ja) 2008-09-03 2010-03-11 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
WO2014050910A1 (ja) 2012-09-26 2014-04-03 武田薬品工業株式会社 固体粒子の製造方法
CA2995617A1 (en) 2017-11-03 2019-05-03 Universite De Montreal Heterocyclic mitochondrial activity inhibitors and uses thereof
KR102929140B1 (ko) * 2023-05-09 2026-02-24 주식회사 베노바이오 Bet 단백질을 저해하는 신규한 벤조사이오펜 유도체 및 이를 이용한 암 치료용 조성물
CN117624052B (zh) * 2024-01-26 2024-04-12 四川益能康生环保科技有限公司 一种用于捕集二氧化碳的离子液体及其制备方法
CN117820251B (zh) * 2024-03-01 2024-05-03 南京桦冠生物技术有限公司 双α-酮酸酰胺类化合物及其组合物
CN118165425B (zh) * 2024-03-13 2024-09-27 福建诏安传琪新材料有限公司 一种无卤阻燃三元乙丙橡胶发泡材料及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359078A (en) * 1989-05-19 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Signal transduction inhibitor compounds
US5334604A (en) 1990-08-23 1994-08-02 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
CA2140440A1 (en) 1992-08-06 1994-02-17 Ellen M. Dobrusin 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
IT1266582B1 (it) 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
US5466610A (en) 1993-09-07 1995-11-14 Eli Lilly And Company Immunoassays for insulin sensitivity enhancers, insulin sensitivity enhancer antibodies, and non-thiazolidinedione insulin sensitivity enhancer compositions
US5480896A (en) 1994-01-27 1996-01-02 American Home Products Corporation Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents
JP4145955B2 (ja) * 1994-09-29 2008-09-03 ノバルティス アクチェンゲゼルシャフト ピロロ〔２，３−ｄ〕ピリミジン及びその使用

Also Published As

Publication number Publication date
CN1349990A (zh) 2002-05-22
CA2260999A1 (en) 1998-01-29
DE69736642T2 (de) 2007-09-20
EP0912562A1 (de) 1999-05-06
WO1998003505A3 (en) 1998-06-25
US6211215B1 (en) 2001-04-03
CA2260999C (en) 2006-07-11
WO1998003505A2 (en) 1998-01-29
EP1270571A1 (de) 2003-01-02
ATE338754T1 (de) 2006-09-15
AU3461697A (en) 1998-02-10
DE69736642D1 (de) 2006-10-19
KR20000065227A (ko) 2000-11-06
EP1270571B1 (de) 2006-09-06
ID17851A (id) 1998-01-29
CN1223653A (zh) 1999-07-21

Similar Documents

Publication Publication Date Title
CN1349990A (zh) 杂环化合物、其制备和用途
CN1146542C (zh) 苯甲酰胺衍生物及其作为细胞因子抑制剂的用途
CN1196703C (zh) 作为cdk2抑制剂的吡唑并苯并二氮䓬
CN1313450C (zh) 速激肽受体拮抗剂
CN1616386A (zh) 用于制备异噻唑衍生物的中间体
CN1714092A (zh) 作为蛋白激酶抑制剂的噻吩并[3,2－b]吡啶－6－腈和噻吩并[2,3－b]吡啶－5－腈
CN1141631A (zh) 新的任选取代的苯基咪唑烷、中间体及其制备方法，作为药物的应用和含有它们的药物组合物
CN1021823C (zh) 治疗哮喘、关节炎等疾病用的取代的苯并二氢吡喃化合物的制品方法
CN1636005A (zh) 苯并噻嗪酮和苯并噁嗪酮化合物
CN1688582A (zh) 稠合吡咯－嘧啶衍生物
HK1042895A1 (zh) 三环吡唑衍生物
CN1329614A (zh) 稠合的哒嗪衍生物、它们的制备方法和用途
CN1898205A (zh) 吲哚满酮衍生物及其在治疗疾病状态如癌症中的用途
HK1045687A1 (zh) 作為抗腫瘤劑的4，5，6，7-四氫吲唑衍生物
CN1216531A (zh) 用作内皮缩血管肽受体拮抗剂的吲哚衍生物
CN1300285A (zh) 羟基亚氨基链烷酸衍生物
CN1070173C (zh) 用作药物的苯甲酰基胍衍生物
CN1276790A (zh) 酰胺基噻唑衍生物及其制备方法与药物组合物
CN1553916A (zh) 用作gabaa受体配体的杂芳基取代的稠合双环杂芳基化合物
CN1230187A (zh) 作为蛋白质酪氨酸激酶抑制剂的二环杂芳族化合物
CN1173497A (zh) 含杂环碳酸衍生物
CN1377346A (zh) 2－吡唑啉－5－酮
CN1100417A (zh) N-杂芳基-n＇-苯脲衍生物及其生产和应用
CN1056879A (zh) 吡咯衍生物及其制备方法
CN101080411A (zh) 作为mch受体拮抗剂的噻唑并吡啶酮衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee